German pharmaceutical company Boehringer Ingelheim has expanded its collaboration with US-based Datavant to bolster its real-world evidence (RWE) initiatives.
Boehringer Ingelheim will use the US health information technology company’s privacy-preserving tokenisation and data connectivity technologies.
The German drugmaker aims to enhance clinical development and launch strategies for 75 additional clinical trials and new molecular entities (NMEs).
By using Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim can efficiently explore third-party data sources without transferring or sharing underlying data.
The approach simplifies data discovery, transformation, and connectivity within Boehringer’s secure research environment, allowing integration of real-world data into drug development.
Boehringer Ingelheim executive director and real-world evidence analytics centre of excellence head Paul Petraro said: “Our investment in real-world data underscores Boehringer Ingelheim’s commitment to using cutting-edge technologies to advance medical research.
“By expanding this approach across more trials and commercial launches, we are positioned to drive more personalised and cost-effective treatments, ultimately transforming patient care.”
Datavant enables data connectivity across the healthcare ecosystem, facilitating the movement of over 60 million healthcare records among thousands of organisations.
Using its technology across a broad portfolio of trials aims to advance the integration of real-world data, enabling precise insights into treatment and long-term health outcomes.
The phased rollout of tokenisation will ensure seamless integration with Boehringer Ingelheim’s existing research infrastructure.
The collaboration seeks to establish a robust framework for future studies and demonstrate the value of a cloud-first tokenisation and data discovery strategy.
Datavant life sciences, ecosystem, and public sector GM and president Arnaub Chatterjee said: “We are honoured to support Boehringer Ingelheim in revolutionising patient care through a pioneering data strategy.
“By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research. This partnership exemplifies how technology can reshape healthcare and improve patient outcomes.”
Recently, Boehringer Ingelheim and Cue Biopharma have teamed up to develop and commercialise CUE-501, a treatment for autoimmune and inflammatory diseases.
